Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06180889 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 17, 2025 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 240 to confirmed 241 · Site details revisedv3 Show 2 more changesShow less
    • Enrollment target: estimated 240 to confirmed 241
    • Site details revised
  2. Start date changed from estimate of Dec 15, 2023 to Dec 20, 2023v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Trial Details
NCT Number NCT06180889
Lead Sponsor Suzhou Alphamab Co., Ltd.
Conditions Knee Arthroplasty, Total
Enrollment 241 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov